Background: Primary growth hormone insensitivity (GHI) and triple A syndrome are rare autosomal recessive disorders. Case Report: The patient, a 12-year-old boy from consanguineous parents, was referred for short stature at the age of 7 years (height: -5.4 SD score). He had low serum insulin-like growth factor I (IGF-I) and IGF binding protein 3 and a blunted IGF-I response to recombinant human GH; molecular analysis of the GH receptor disclosed a homozygous A-1→G-1 at the 5′ pseudoexon 6Ψ splice site. Recombinant IGF-I therapy (mecasermin, Increlex®, twice daily) initiated at the age of 9 years resulted in an increase of height velocity (HV) from 4.0 to 9.5 cm/year. At the age of 10.5 years, he presented with asthenia, anorexia, weight loss, a decrease in HV and very low cortisol levels; adrenal insufficiency was confirmed and glucocorticoid therapy was initiated. Subsequent peripheral motor neuropathy, achalasia and alacrima raised the suspicion of triple A syndrome, which was confirmed by the presence of a homozygous R194X mutation in the AAAS gene. Conclusion: This unusual combination of diseases, to our knowledge, has not been reported to date. Although the patient responded to recombinant IGF-I therapy for GHI, we hypothesize that the treatment could have had an inhibitory effect on 11β-hydroxysteroid dehydrogenase type 1 activity, thereby reducing the availability of cortisol and precipitating adrenal insufficiency.

Keywords:
Adrenal insufficiency, Insulin-like growth factor I, Growth, Cortisol, Triple A syndrome, Growth hormone insensitivity
1.
Laron Z, Pertzelan A, Mannheimer S: Genetic pituitary dwarfism with high serum concentrations of growth hormone: a new inborn error of metabolism? Isr J Med Sci 1966;2:152-155.
2.
Laron Z: Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-1044.
3.
Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hübner C: Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2006;2:395-407.
4.
Rosenfeld RG, Belgorosky A, Camacho-Hubner: Defects in growth hormone receptor signalling. Trends Endocrinol Metab 2007;18:134-141.
5.
Allgrove J, Clayden GS, Grand DB, Macaulay JC: Familial glucocorticoid deficiency with achalasia of the cardia and deficient tear production. Lancet 1978;1:1284-1286.
6.
Gazarian M, Cowell CT, Bonney M, Grigor WG: The ‘4A' syndrome: adrenocortical insufficiency associated with achalasia, alacrima, autonomic and other neurological abnormalities. Eur J Pediatr 1995;154:18-23.
7.
Handschug K, Sperling S, Yoon SJ, Henning S, Clark AJ, Huebner A: Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet 2001;10:283-290.
8.
Houlden H, Smith S, De Carvalho M, Blake J, Mathias C, Wood NW: Clinical and genetic characterization of families with triple A (Allgrove syndrome). Brain 2002;125:2681-2690.
9.
Ferrández-Longás A, Mayayo E, Labarta JI, Bagué L, Puga B, Rueda C, Ruiz-Echarri M, Labena C: Estudio longitudinal de crecimiento y desarrollo. Centro Andrea Prader. Zaragoza 1980-2002. Patrones de crecimiento y desarrollo en España. Atlas de gráficas y tablas. Madrid, Ergon, 2004, pp 61-115.
10.
Greulich WW, Pyle SI: Radiographic atlas of skeletal development of the hand and wrist. Stanford, Stanford University Press, 1959.
11.
Soldin OP, Dahlin JR, Gresham EG, King J, Soldin SJ: Immulite 2000 age and sex-specific reference intervals for alpha fetoprotein, homocysteine, insulin, insulin-like growth factor-1, insulin-like growth factor binding protein-3, C-peptide, immunoglobulin E and intact parathyroid hormone. Clin Biochem 2008;41:937-942.
12.
Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO: Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet 2001;69:641-646.
13.
Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG; International ALS Collaborative Group: Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009;72:129-141.
14.
Hwa V, Nadeau K, Wit JM, Rosenfeld RG: STAT5b deficiency: lessons from STAT5b gene mutation. Best Res Clin Endocrinol Metab 2011;25:61-75.
15.
David A, Hwa V, Metherell LA, Netchine I, Camacho-Hübner C, Clark AJL, Rosenfeld RG, Savage MO: Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. Endocr Rev 2011;32:472-497.
16.
Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J: Growth hormone (GH) insensitivity due to pituitary GH receptor deficiency. Endocr Rev 1994;15:369-390.
17.
Maamra M, Milkward A, Esfahani HZ, Abbott LP, Metherell LA, Savage MO: A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signalling. J Endocrinol 2006;188:251-261.
18.
David A, Camacho-Hübner C, Bhangoo A, Rose SJ, Miraki-Moud F, Akker SA: An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes. J Clin Endocrinol Metab 2007;92:655-659.
19.
Rosenfeld RG: IGF-I therapy in growth disorders. Eur J Endocrinol 2007;157(suppl. 1):S57-60.
20.
Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE: Long-term treatment with recombinant insulin-like growth factor (IGF-I) in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-910.
21.
Collett-Solberg PF, Misra M: The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008;93:10-18.
22.
Tullio-Pelet A, Salomon R, Hadj-Rabia S, Mugnier C, de Laet MH, Chaouachi B: Mutant WD-repeat protein in triple-A syndrome. Nat Genet 2000;26:332-335.
23.
Reshmi-Skarja S, Huebner A, Handschug K, Finegold DN, Clark AJ, Gollin SM: Chromosomal fragility in patients with triple A syndrome. Am J Med Genet 2003;117A:30-36.
24.
Prpic I, Huebner A, Persic M, Handschug K, Pavletic M: Triple A syndrome: genotype-phenotype assessment. Clin Genet 2003;63:415-417.
25.
Sandrini F, Farmakidis C, Kirschner LS, Wu SM, Tullio-Pellet A, Lyonnet S: Spectrum of mutations of the AAAS gene in Allgrove syndrome: lack of mutations in six kindreds with isolated resistance to corticotrophin. J Clin Endocrinol Metab 2001;86:5433-5437.
26.
Milenkovic T, Koehler K, Krumbholz M, Zivanovic S, Zdravkovic D, Huebner A: Three siblings with triple A syndrome with a novel frameshift mutation in the AAAS gene and a review of 17 independent patients with the frequent p.Ser263Pro mutation. Eur J Pediatr 2008;167:1049-1055.
27.
Milenkovic T, Zdravkovic D, Savic N, Todorovic S, Mitrovic K, Koehler K, Huebner A: Triple A syndrome: 32 years experience of a single centre (1977-2008). Eur J Pediatr 2010;169:1323-1328.
28.
Cronshaw JM, Matunis MJ: The nuclear pore complex protein ALADIN is mislocalized in triple A syndrome. Proc Natl Acad Sci 2003;100:5823-5827.
29.
Storr HL, Kind B, Parfitt DA, Chapple JP, Lorenz M, Koehler K: Deficiency of ferritin heavy-chain nuclear import in triple A syndrome implies nuclear oxidative damage as the primary disease mechanism. Mol Endocrinol 2009;23:2086-2094.
30.
Kinjo S, Takemoto M, Miyako K, Kohno H, Tanaka T, Katsumata N: Two cases of Allgrove syndrome with mutations in the AAAS gene. Endocr J 2004;51:473-477.
31.
Dusek T, Korsik M, Koehler K, Perkovic Z, Huebner A: A novel AAAS mutation (R194X) in a patient with a triple A syndrome. Horm Res 2006;65:171-176.
32.
Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP: The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) 1998;48:153-162.
33.
Agha A, Monson JP: Modulation of glucocorticoid metabolism by the growth hormone-IGF-1 axis. Clin Endocrinol (Oxf) 2007;66:459-465.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.